These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8794991)

  • 1. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro.
    Coleman MD; Pahal KK; Gardiner JM
    J Pharm Pharmacol; 1996 Apr; 48(4):401-6. PubMed ID: 8794991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro.
    Coleman MD; Jacobus DP
    Biochem Pharmacol; 1993 Mar; 45(5):1027-33. PubMed ID: 8461032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro--II. Movement of dapsone across a semipermeable membrane into erythrocytes and plasma.
    Coleman MD; Jacobus DP
    Biochem Pharmacol; 1993 Oct; 46(8):1363-8. PubMed ID: 8240384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the differential sensitivity between diabetic and non-diabetic human erythrocytes to monoacetyl dapsone hydroxylamine-mediated methaemoglobin formation in vitro.
    Coleman MD; Ogg MS; Holmes JL; Gardiner JM; Jacobus DP
    Environ Toxicol Pharmacol; 1996 Apr; 1(2):97-102. PubMed ID: 21781668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The methaemoglobin forming and GSH depleting effects of dapsone and monoacetyl dapsone hydroxylamines in human diabetic and non-diabetic erythrocytes in vitro.
    Coleman MD; Holden LJ
    Environ Toxicol Pharmacol; 2004 May; 17(1):55-9. PubMed ID: 21782713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. III: Effect of diabetes.
    Coleman MD; Simpson J; Jacobus DP
    Biochem Pharmacol; 1994 Oct; 48(7):1341-7. PubMed ID: 7945431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions.
    Reilly TP; Woster PM; Svensson CK
    J Pharmacol Exp Ther; 1999 Mar; 288(3):951-9. PubMed ID: 10027831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. IV: Implications for the development of agranulocytosis.
    Coleman MD; Simpson J; Jacobus DP
    Biochem Pharmacol; 1994 Oct; 48(7):1349-54. PubMed ID: 7945432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methaemoglobin formation due to nitrite, disulfiram, 4-aminophenol and monoacetyldapsone hydroxylamine in diabetic and non-diabetic human erythrocytes in vitro.
    Coleman MD; Hayes PJ; Jacobus DP
    Environ Toxicol Pharmacol; 1998 Jan; 5(1):61-7. PubMed ID: 21781851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man.
    Tingle MD; Mahmud R; Maggs JL; Pirmohamed M; Park BK
    J Pharmacol Exp Ther; 1997 Nov; 283(2):817-23. PubMed ID: 9353403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomonitoring of aromatic amines V: acetylation and deacetylation in the metabolic activation of aromatic amines as determined by haemoglobin binding.
    Zwirner-Baier I; Neumann HG
    Arch Toxicol; 1998; 72(8):499-504. PubMed ID: 9765065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadal influence on the metabolism and haematological toxicity of dapsone in the rat.
    Coleman MD; Tingle MD; Winn MJ; Park BK
    J Pharm Pharmacol; 1990 Oct; 42(10):698-703. PubMed ID: 1982141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteers.
    Edstein MD; Rieckmann KH
    Chemotherapy; 1993; 39(4):235-41. PubMed ID: 8325124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disposition of dapsone in cirrhosis.
    May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
    May DG; Porter JA; Uetrecht JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1990 Dec; 48(6):619-27. PubMed ID: 2249373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic drugs aniline and dapsone induce iron release in erythrocytes and increase the free iron pool in spleen and liver.
    Ciccoli L; Ferrali M; Rossi V; Signorini C; Alessandrini C; Comporti M
    Toxicol Lett; 1999 Oct; 110(1-2):57-66. PubMed ID: 10593595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro haematotoxic effects of three methylated hydroxylamines.
    Spooren AA; Evelo CT
    Arch Toxicol; 1997; 71(5):299-305. PubMed ID: 9137808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system.
    Tingle MD; Coleman MD; Park BK
    Br J Clin Pharmacol; 1990 Dec; 30(6):829-38. PubMed ID: 2288829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding.
    Bordin L; Fiore C; Zen F; Coleman MD; Ragazzi E; Clari G
    Br J Pharmacol; 2010 Nov; 161(5):1186-99. PubMed ID: 20662842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets.
    Mirochnick M; Clarke DF; McNamara ER; Cabral H
    Am J Health Syst Pharm; 2000 Oct; 57(19):1775-7. PubMed ID: 11030029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.